CCR9 and adenocarcinoma: This disparity may arise from histology-specific modulation of downstream effectors: adenocarcinomas exhibit higher serum CCL25 levels (20), while CCR9-driven upregulation of VEGF, MMP-2, and MMP-9 promotes angiogenesis and metastatic dissemination (41).